Submitted by jwr@researchtop... on Mon, 02/03/2020 - 15:52
CME Test
CME information and faculty disclosures
Select publications
Related video program
Listen to streaming audio
right from your computer
Download program
to your desktop
Subscribe to podcast
to have this and future issues delivered to your iTunes library
Audio Highlights
Track 1:
Improved treatment outcomes and impact on the incidence of brain metastases in patients with non-small cell lung cancer (NSCLC)
Track 2:
Case (Dr Gubens):
A man in his mid-50s with adenocarcinoma of the lung with an EGFR exon 19 deletion mutation, asymptomatic brain lesions and significant systemic burden
Track 3:
Clinical care of patients with NSCLC brain metastases alone and no systemic disease
Track 4:
Diagnosis of radiation necrosis
Track 5:
Activity of the third-generation EGFR tyrosine kinase inhibitor (TKI) osimertinib in patients with NSCLC and CNS metastases
Track 6:
Mechanism of action of osimertinib in the brain and effect on CNS disease progression
Track 7:
Risks of whole-brain radiation therapy; role of hippocampus sparing and memantine administration in minimizing the adverse effects of whole-brain radiation therapy
Track 8:
Comparison of survival outcomes with stereotactic radiation therapy and EGFR TKIs
Track 9:
Case (Dr Gubens):
A man in his late 40s with metastatic NSCLC with an ALK rearrangement and large asymptomatic brain metastases
Track 10:
Role of other TKIs (ie, BRAF, MET, HER2 inhibitors) in NSCLC with CNS metastases
Track 11:
Antitumor effect of ALK inhibitors in patients with CNS metastases
Track 12:
Practical issues in the management of CNS metastases: edema, symptomatic CNS metastases and oligoprogression
Track 13:
Managing CNS metastases with leptomeningeal involvement
Track 14:
Case (Dr Gubens):
A man in his early 40s with metastatic adenocarcinoma of the lung with an EGFR L858R mutation responds to first-line osimertinib for 2 years but then develops 2 new asymptomatic punctate parenchymal metastases and extensive leptomeningeal involvement
Track 15:
Symptoms of CNS metastases with leptomeningeal involvement; challenges in diagnosis
Track 16:
Case (Dr Gubens):
A woman in her late 60s with metastatic adenocarcinoma of the lung, no targetable tumor mutations and a PD-L1 tumor proportion score (TPS) of 80%
Track 17:
Outlook on the use of TKIs for patients with CNS metastases
Track 18:
Potential for combining TKIs with chemotherapy in the management of CNS metastases
Track 19:
Activity and safety of EGFR TKIs in combination with anti-PD-1/PD-L1 antibodies
FACULTY
Gregory J Riely, MD, PhD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York
EDITOR
Neil Love, MD
Research To Practice
Miami, Florida